Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TransMedics (TMDX) Net Margin (2018 - 2026)

TransMedics has reported Net Margin over the past 8 years, most recently at 11.56% for Q4 2025.

  • For Q4 2025, Net Margin rose 3478.0% year-over-year to 11.56%; the TTM value through Dec 2025 reached 17.47%, up 1739.0%, while the annual FY2025 figure was 0.18%, 10.0% up from the prior year.
  • Net Margin for Q4 2025 was 11.56% at TransMedics, down from 16.91% in the prior quarter.
  • Over five years, Net Margin peaked at 370.43% in Q4 2021 and troughed at 239.46% in Q3 2021.
  • A 5-year average of 11.05% and a median of 4.13% in 2023 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: skyrocketed 45317bps in 2021 and later plummeted -39185bps in 2022.
  • Year by year, Net Margin stood at 370.43% in 2021, then tumbled by -106bps to 21.42% in 2022, then surged by 269bps to 36.22% in 2023, then plummeted by -164bps to 23.22% in 2024, then soared by 150bps to 11.56% in 2025.
  • Business Quant data shows Net Margin for TMDX at 11.56% in Q4 2025, 16.91% in Q3 2025, and 22.17% in Q2 2025.